AstraZeneca commits USD2B to expand Maryland manufacturing operations

USA—British pharmaceutical company AstraZeneca plans to invest USD2 billion to expand its manufacturing operations in Maryland, marking the largest private investment in the state in over a decade.

The investment will nearly double production capacity at the company’s flagship biologics plant in Frederick, Maryland.

For the first time, the facility will also manufacture AstraZeneca’s rare disease products.

Additionally, the company will establish a clinical manufacturing site in Gaithersburg, Maryland, located 25 miles southeast of Frederick.

AstraZeneca acquired the Gaithersburg facility last month through a USD60 million lease transfer from vaccine specialist Novavax, which previously used the site as its headquarters.

The new facility will produce molecules for medical trials. These expansions will create 200 additional jobs in Frederick and 100 more in Gaithersburg.

The company already maintains a significant presence in Maryland, employing 4,000 people at its research and development campus in Gaithersburg.

In May, AstraZeneca opened a USD300 million cell therapy manufacturing facility in nearby Rockville, which employs at least 150 workers.

Maryland’s lieutenant governor, Aruna Miller, noted at the May ribbon-cutting ceremony that no life sciences company employs more people in the state than AstraZeneca.

During a press conference at the Frederick site, AstraZeneca CEO Pascal Soriot joked about becoming an honorary Marylander, noting he spends most of his time in Gaithersburg.

He also mentioned maintaining an apartment in Arlington, Virginia, to share his affection for the region.

Soriot has focused considerable attention on the Washington, D.C. area recently.

In July, he announced the company’s plan to invest US50 billion across the United States.

Then, in October, he joined President Donald Trump at the White House to announce an agreement to sell drugs to Medicaid patients at most-favored-nation pricing, matching the lowest prices offered in other developed countries.

Last month, Soriot unveiled plans to construct a USD4.5 billion active pharmaceutical ingredients plant near Charlottesville, Virginia, which will create 600 jobs.

Maryland Governor Wes Moore proclaimed the state’s intention to lead the nation’s life science industry during an event on November 21.

He confirmed that Maryland would provide a 10% investment match for AstraZeneca’s commitment.

These investments respond to President Trump’s threats to tax imported drugs. Last month, Trump proposed a 100% tax on imported pharmaceuticals, with exemptions for companies building U.S. manufacturing facilities.

Other pharmaceutical companies announcing major U.S. investments include Merck with USD70 billion, Roche with USD50 billion, and Johnson & Johnson with USD55 billion.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on LinkedIn for updates.